Time-sensitive policy posts distinguish confirmed action from developing information and link to primary sources whenever available.
California Medicaid & CHIP Implementation Update
California publishes state-only pathway for affected youth care
California HCAI now directs specified youth gender-affirming medications and surgeries that lose federal Medicaid or CHIP reimbursement on October 13 to a state-only grant pathway outside Medi-Cal. Other gender-affirming services, complication care, and adult care remain reimbursable through Medi-Cal. Existing youth hormone prescriptions receive a Medi-Cal transition through April 12, 2027; the transition excludes puberty blockers, surgeries, and newly started hormones. Program-administration and further medication-access details remain forthcoming.
Federal rescission package targets LGBTQIA+ health research funds
The White House announced a pocket-rescission package that includes $28 million in HHS research funding and identifies several transgender-health-access, insurance-coverage, patient-safety, and LGBTQIA+ primary-care projects as examples. This is a research-funding action—not a Medicare or Medicaid coverage decision, clinical restriction, or nationwide care ban. Project-specific termination notices and implementation dates were not identified in the announcement.
Ryan White funding-conditions challenge reaches federal-court hearing
A federal court held a hearing in American Academy of HIV Medicine v. HRSA concerning challenged Ryan White HIV/AIDS Program grant conditions that restrict use of program funds for gender-affirming medical care and impose sex-based conditions affecting care for transgender patients. The court did not rule from the bench, and no injunction or merits decision was identified. The conditions concern Ryan White grants and covered recipients; they are not a nationwide ban on all HIV care, gender-affirming care, Medicaid, Medicare, or private insurance.
NYU Langone and UPMC agreements narrow youth-care availability
DOJ announced provider-specific agreements under which NYU Langone and UPMC will stop providing specified gender-affirming medications and surgeries to minors. The agreements affect those named health systems, not New York or Pennsylvania statewide. DOJ states that the resolved claims were allegations only, with no determination of liability, and both providers denied the allegations.
Court dismisses one Title X funding challenge as unripe
A federal court dismissed without prejudice a provider-association challenge to the FY2027 Title X funding notice as unripe. The court did not decide whether the challenged priorities are lawful; the funding competition continues, and the ruling does not dispose of the separate multistate Title X case pending in Maryland.
North Dakota Supreme Court upholds youth-care restriction
The North Dakota Supreme Court unanimously affirmed the judgment upholding the state's restriction on specified gender-affirming medical care for minors. The law remains enforceable unless later court action changes that posture. The decision resolves the state constitutional claims presented in this case; it does not create a nationwide restriction.
Federal court leaves HHS provider-funding directive blocked
A federal judge denied the government's request to narrow the April judgment setting aside HHS Secretary Kennedy's December 2025 provider-funding directive. That directive remains blocked. The order does not invalidate state youth-care restrictions or the separate CMS Medicaid and CHIP funding rule scheduled to take effect October 13.
Tierra Walker's family and estate filed a Bexar County petition alleging that Texas abortion-enforcement policies and care by named public-health defendants contributed to her December 2024 death. The plaintiffs seek damages and declarations concerning specified Texas abortion restrictions. The allegations have not been adjudicated, and filing the case did not stay, enjoin, or invalidate Texas law.
Ninth Circuit upholds Washington reproductive-health coverage framework
The Ninth Circuit upheld Washington's Reproductive Parity Act and conscience statute against the Free Exercise and church-autonomy claims presented in Cedar Park Assembly of God v. Kuderer. The ruling leaves Washington's state-regulated abortion-coverage and conscience framework in place; it does not create a nationwide coverage mandate and remains subject to possible further appellate review.
HHS published a survey-based report claiming associations among endorsement of gender-affirming professional guidance, a measure of left-wing authoritarianism, and willingness to justify political violence. The report acknowledges that its cross-sectional design cannot establish causation. It is not a rule, clinical guideline, coverage or funding decision, enforcement directive, or provider agreement and does not itself change healthcare access or legal obligations.
California documents investments supporting gender-affirming-care access
California has officially documented $30 million over three years for uncompensated gender-affirming care and abortion services and $26 million over three years to stabilize and expand its gender-affirming-care provider network. The investments support access, but the announcement does not establish the Medi-Cal or CHIP claims process that will apply after the federal funding restriction takes effect October 13.
Massachusetts documents state funding backstop for gender-affirming care
Massachusetts has appropriated state money to its Affirming Health Care Trust Fund, which may be spent without further appropriation on gender-affirming healthcare services. The fund provides a documented state funding backstop, but no official MassHealth claims or member notice reviewed yet explains how affected coverage will operate after the federal Medicaid and CHIP funding restriction takes effect October 13.
Mount Sinai agreement narrows youth-care availability in New York
DOJ announced a provider-specific agreement under which Mount Sinai will stop administering puberty blockers and cross-sex hormones and performing surgical gender-affirming procedures for minors. The agreement affects the named health system rather than changing New York law statewide. DOJ states that the resolved claims were allegations only, with no determination of liability, and Mount Sinai denied the allegations.
States challenge federal Medicaid and CHIP funding restriction
A coalition of 20 states and the District of Columbia, joined by Pennsylvania's governor, filed suit challenging CMS's August 13 Medicaid and CHIP funding rule for defined gender-affirming interventions furnished to minors. The complaint seeks to set aside and block the rule, but filing it did not itself create an injunction; the rule remains scheduled for October 13 unless a court or agency changes that posture.
Three jurisdictions add or expand PrEP access protections
The map now reflects enacted PrEP and PEP access protections in Delaware, the District of Columbia, and Massachusetts. Delaware's mandate applies after December 31, 2027; D.C.'s principal no-cost-sharing and utilization protections apply to plans issued or renewed on or after January 1, 2027; Massachusetts protections are in effect, with private-plan duties attaching as applicable policies are issued, delivered, or renewed.
DOJ provider agreements narrow youth-care availability at named hospitals
DOJ announced provider-specific agreements under which Connecticut Children’s committed not to provide specified gender-affirming medications or surgeries to minors. The announcement follows agreements involving Texas Children’s and Cleveland Clinic. These commitments affect the named facilities; they are not statewide or nationwide care bans, and DOJ states that the resolved claims were allegations only with no determination of liability.
States challenge new FY2027 Title X grant priorities
HHS's FY2027 Title X funding notice sets new priorities for future family-planning grant recipients, including ending DEI policies across OASH programs and reducing what the notice calls overmedicalization. A multistate coalition filed suit challenging the conditions. The case has not yet produced an injunction, and the notice concerns the FY2027 award cycle rather than an immediate nationwide termination of current Title X services.
Second Circuit leaves New York patient-record injunction in place
The Second Circuit denied the federal government's request to pause the preliminary injunction in Coe v. Blanche while the appeal proceeds. The New York injunction protecting the covered patient identities and sensitive health information remains in place; the appellate court did not issue a final merits decision or a nationwide ruling.
New Jersey strengthens protections for reproductive and gender-affirming healthcare
Governor Mikie Sherrill signed S2260/A2218, effective immediately. The law strengthens protections involving reproductive healthcare and expressly expands New Jersey shield-law protections to include gender-affirming care. The change affects areas including patient information, certain out-of-state investigations and proceedings, professional protections, access interference, and care that is lawful in New Jersey.
Ethical documentation workshop moved to Past Education
What We Write Matters: Ethical Documentation for LGBTQIA+ Clients was held on August 7, 2026. The event is preserved as Past Education and is no longer presented as an upcoming or registerable live workshop. Any separately available workshop materials are identified accurately and do not imply attendance or continuing-education credit.
LGBTQIA+ Health NJ receives federal 501(c)(3) recognition
The Internal Revenue Service issued LGBTQIA+ Health NJ its determination recognizing the organization as tax-exempt under Section 501(c)(3), with exemption effective June 22, 2026. The organization is classified as a public charity under Section 509(a)(2).
A Douglas County District Court temporarily blocked enforcement of Kansas SB 63 while Loe v. Kansas proceeds. The restriction remains enacted but is not treated as currently enforceable during the injunction; the state has announced an appeal.
New Hampshire profile corrected for medication and surgical restrictions
New Hampshire HB 377 took effect January 1, restricting new puberty-blocker and specified hormone treatment for minors while allowing treatment begun before that date to continue. Separate state law also restricts specified gender-related surgeries for minors. The map now reflects the medication, surgical, enforcement, and grandfathering provisions together.
